Johnson & Johnson (NYSE:JNJ) Stock Position Lessened by Cambridge Trust Co.

Cambridge Trust Co. lessened its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 269,325 shares of the company’s stock after selling 4,929 shares during the period. Johnson & Johnson accounts for approximately 2.1% of Cambridge Trust Co.’s portfolio, making the stock its 8th largest holding. Cambridge Trust Co.’s holdings in Johnson & Johnson were worth $47,576,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of Johnson & Johnson by 18.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after buying an additional 3,912,430 shares during the last quarter. FMR LLC increased its position in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. GQG Partners LLC increased its position in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Johnson & Johnson by 52.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after purchasing an additional 2,093,392 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on JNJ shares. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Piper Sandler lowered their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Citigroup raised their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $174.73.

Johnson & Johnson Stock Performance

JNJ stock opened at $152.38 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The stock has a market cap of $396.84 billion, a P/E ratio of 22.61, a P/E/G ratio of 2.65 and a beta of 0.54. The firm has a 50 day simple moving average of $161.97 and a 200 day simple moving average of $167.88. Johnson & Johnson has a 52 week low of $150.71 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.13 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 67.06%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.